Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.

By R. Neer, C. Arnaud, J. Zanchetta, R. Prince, G. Gaich, J. Reginster, A. Hodsman, E. Eriksen, S. Ish-shalom, H. Genant and 2 more. New England Journal of Medicine, 2001

4,531 citations recorded by the source corpus.

Subfields: Nephrology, Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/78a2c8885b0581e742a0e09b3015f9bd00504a0d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Nephrology

1. C. Rosen

In Oncology

1. S. Manolagas
2. E. Eriksen
3. S. Khosla
4. R. Jilka
5. Chris Cooper
6. J. Reginster
7. S. Kousteni
8. R. Rizzoli

In Orthopedics and Sports Medicine

1. Chris Cooper
2. J. Reginster
3. S. Manolagas
4. R. Rizzoli
5. E. Eriksen
6. on behalf of the International Osteoporosis Foundation
7. J. Kanis
8. C. Rosen

Citations in the corpus

• Incidence and Economic Burden of Osteoporosis‐Related Fractures in the United States, 2005–2025 (2007, background): “These results illustrate the importance of osteoporosis treatments with shown efficacy beyond the spine and across multiple skeletal sites such as bisphosphonates,(27–29) PTH,(30) and strontium ranelate.”
• An overview and management of osteoporosis. (2017, background): “Serum calcium, PTH, and 25 (OH) D levels should be checked before treatment (50).”
• Effects of Daily Treatment with Parathyroid Hormone on Bone Microarchitecture and Turnover in Patients with Osteoporosis: A Paired Biopsy Study * (2001, background): “small clinical trial (11) and a large multicenter trial (12) have”
• Sex steroids and bone. (2002, result): “…of a recent clinical trial with daily injections of PTH for 18 months support strongly this contention by showing that the anabolic property of PTH restores BMD in the normal range and prevents bone fractures to levels much greater than those seen with antiresorptive agents (Neer et al., 2001).”
• Bone grafts and biomaterials substitutes for bone defect repair: A review (2017, background): “fracture in osteoporotic bone [240], a growing number of studies have suggested the ability of PTH to accelerate fracture healing”
• The clinician’s guide to prevention and treatment of osteoporosis (2022, background): “Drug efficacy Teriparatide reduces risk of vertebral fractures by 65–77%, and non-vertebral fractures by 35–53% in patients with osteoporosis, after an average of 18months of therapy [180].”
• Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure (2003, background): “Introduction: We studied the ability of teriparatide (rDNA origin) injection [rhPTH(1-34), TPTD] to improve both”
• From space to Earth: advances in human physiology from 20 years of bed rest studies (1986–2006) (2007, background): “Other pharmacological agents like selective estrogen receptor modulators (SERM), parathyroid hormone (PTH) and strontium ranelate have been successfully tested and found to decrease the risk of vertebral and non-vertebral fractures in postmenopausal women (Delmas et al. 2002; Roux et al. 2006; Weins”